Case report: therapeutic monitoring of vancomycin in an acute liver failure patient with anuria under high-flow continuous hemodiafiltration.
Anuric
High flow continuous hemodiafiltration
Therapeutic drug monitoring
Vancomycin
Journal
Journal of pharmaceutical health care and sciences
ISSN: 2055-0294
Titre abrégé: J Pharm Health Care Sci
Pays: England
ID NLM: 101672177
Informations de publication
Date de publication:
01 May 2023
01 May 2023
Historique:
received:
15
12
2022
accepted:
24
03
2023
medline:
1
5
2023
pubmed:
1
5
2023
entrez:
30
4
2023
Statut:
epublish
Résumé
High-flow continuous hemodiafiltration (HF-CHDF) combines diffusive and convective solute removal and is employed for artificial liver adjuvant therapy. However, there is no report on dosage planning of vancomycin (VCM) in patients with acute liver failure under HF-CHDF. A 20-year-old woman (154 cm tall, weighing 50 kg) was transferred to the intensive care unit (ICU) with acute liver failure associated with autoimmune liver disease. On the following day, HF-CHDF was started due to elevated plasma ammonia concentration. On ICU day 8, VCM was started for suspected pneumonia and meningitis (30 mg/kg loading dose, then 20 mg/kg every 12 hrs). However, on ICU day 10, VCM blood concentration was under the limit of detection (< 3.0 μg/mL) and the patient developed anuria. The VCM dose was increased to 20 mg/kg every 6 hrs. Calculation with a one-compartment model using the HF-CHDF blood flow rate as a surrogate for VCM clearance, together with hematocrit and protein binding ratio, predicted a trough VCM blood concentration of 15 μg/mL. The observed concentration was about 12 μg/mL. The difference may represent non-HF-CHDF clearance. Finally, living donor liver transplantation was performed. We report an acute liver failure patient with anuria under HF-CHDF in whom VCM administration failed to produce an effective blood concentration, likely due to HF-CHDF-enhanced clearance. VCM dosage adjustment proved successful, and was confirmed by calculation using a one-compartment model.
Sections du résumé
BACKGROUND
BACKGROUND
High-flow continuous hemodiafiltration (HF-CHDF) combines diffusive and convective solute removal and is employed for artificial liver adjuvant therapy. However, there is no report on dosage planning of vancomycin (VCM) in patients with acute liver failure under HF-CHDF.
CASE PRESENTATION
METHODS
A 20-year-old woman (154 cm tall, weighing 50 kg) was transferred to the intensive care unit (ICU) with acute liver failure associated with autoimmune liver disease. On the following day, HF-CHDF was started due to elevated plasma ammonia concentration. On ICU day 8, VCM was started for suspected pneumonia and meningitis (30 mg/kg loading dose, then 20 mg/kg every 12 hrs). However, on ICU day 10, VCM blood concentration was under the limit of detection (< 3.0 μg/mL) and the patient developed anuria. The VCM dose was increased to 20 mg/kg every 6 hrs. Calculation with a one-compartment model using the HF-CHDF blood flow rate as a surrogate for VCM clearance, together with hematocrit and protein binding ratio, predicted a trough VCM blood concentration of 15 μg/mL. The observed concentration was about 12 μg/mL. The difference may represent non-HF-CHDF clearance. Finally, living donor liver transplantation was performed.
CONCLUSION
CONCLUSIONS
We report an acute liver failure patient with anuria under HF-CHDF in whom VCM administration failed to produce an effective blood concentration, likely due to HF-CHDF-enhanced clearance. VCM dosage adjustment proved successful, and was confirmed by calculation using a one-compartment model.
Identifiants
pubmed: 37122008
doi: 10.1186/s40780-023-00283-0
pii: 10.1186/s40780-023-00283-0
pmc: PMC10150540
doi:
Types de publication
Journal Article
Langues
eng
Pagination
15Informations de copyright
© 2023. The Author(s).
Références
Artif Organs. 1996 Nov;20(11):1169-72
pubmed: 8908326
J Infect Chemother. 1999 Jun;5(2):104-107
pubmed: 11810500
Sci Rep. 2019 Jan 29;9(1):909
pubmed: 30696874
ASAIO J. 2011 Nov-Dec;57(6):507-10
pubmed: 21946313
Am J Health Syst Pharm. 2020 May 19;77(11):835-864
pubmed: 32191793
Ther Apher Dial. 2018 Oct;22(5):485-493
pubmed: 29987905
Antimicrob Agents Chemother. 2012 Dec;56(12):6181-5
pubmed: 22985887
Antimicrob Agents Chemother. 1982 Sep;22(3):391-4
pubmed: 7137982
J Clin Pharm Ther. 2020 Oct;45(5):1143-1148
pubmed: 32497268
Antimicrob Agents Chemother. 2011 Dec;55(12):5804-12
pubmed: 21911561
BMC Emerg Med. 2010 May 21;10:10
pubmed: 20492684
Contrib Nephrol. 2010;166:64-72
pubmed: 20472993
J Gastroenterol Hepatol. 2014 Apr;29(4):782-6
pubmed: 24224755
Br J Pharmacol. 2007 Jul;151(5):580-90
pubmed: 17471184
CPT Pharmacometrics Syst Pharmacol. 2018 Apr;7(4):237-250
pubmed: 29446256
Ther Drug Monit. 2018 Jun;40(3):377-380
pubmed: 29494420
Antimicrob Agents Chemother. 2019 Jul 25;63(8):
pubmed: 31109983
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Dec;156(4):342-7
pubmed: 22660225
J Pharm Health Care Sci. 2015 Nov 14;1:31
pubmed: 26819742
Clin Infect Dis. 2012 Aug;55(4):527-33
pubmed: 22573855